These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 27595986)

  • 1. Multifunctional Antibody Agonists Targeting Glucagon-like Peptide-1, Glucagon, and Glucose-Dependent Insulinotropic Polypeptide Receptors.
    Wang Y; Du J; Zou H; Liu Y; Zhang Y; Gonzalez J; Chao E; Lu L; Yang P; Parker H; Nguyen-Tran V; Shen W; Wang D; Schultz PG; Wang F
    Angew Chem Int Ed Engl; 2016 Sep; 55(40):12475-8. PubMed ID: 27595986
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human epicardial adipose tissue expresses glucose-dependent insulinotropic polypeptide, glucagon, and glucagon-like peptide-1 receptors as potential targets of pleiotropic therapies.
    Malavazos AE; Iacobellis G; Dozio E; Basilico S; Di Vincenzo A; Dubini C; Menicanti L; Vianello E; Meregalli C; Ruocco C; Ragni M; Secchi F; Spagnolo P; Castelvecchio S; Morricone L; Buscemi S; Giordano A; Goldberger JJ; Carruba M; Cinti S; Corsi Romanelli MM; Nisoli E
    Eur J Prev Cardiol; 2023 Jun; 30(8):680-693. PubMed ID: 36799940
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological characterization of mono-, dual- and tri-peptidic agonists at GIP and GLP-1 receptors.
    Yuliantie E; Darbalaei S; Dai A; Zhao P; Yang D; Sexton PM; Wang MW; Wootten D
    Biochem Pharmacol; 2020 Jul; 177():114001. PubMed ID: 32360365
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of CRISPR/Cas9-engineered INS-1 pancreatic β cells to define the pharmacology of dual GIPR/GLP-1R agonists.
    Naylor J; Suckow AT; Seth A; Baker DJ; Sermadiras I; Ravn P; Howes R; Li J; Snaith MR; Coghlan MP; Hornigold DC
    Biochem J; 2016 Sep; 473(18):2881-91. PubMed ID: 27422784
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Dual GLP-1/GIP Receptor Agonist Does Not Antagonize Glucagon at Its Receptor but May Act as a Biased Agonist at the GLP-1 Receptor.
    Al-Zamel N; Al-Sabah S; Luqmani Y; Adi L; Chacko S; Schneider TD; Krasel C
    Int J Mol Sci; 2019 Jul; 20(14):. PubMed ID: 31330984
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel glucagon-like peptide-1 (GLP-1)/glucagon hybrid peptide with triple-acting agonist activity at glucose-dependent insulinotropic polypeptide, GLP-1, and glucagon receptors and therapeutic potential in high fat-fed mice.
    Gault VA; Bhat VK; Irwin N; Flatt PR
    J Biol Chem; 2013 Dec; 288(49):35581-91. PubMed ID: 24165127
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stapled, Long-Acting Xenopus GLP-1-Based Dual GLP-1/Glucagon Receptor Agonists with Potent Therapeutic Efficacy for Metabolic Disease.
    Han C; Sun Y; Yang Q; Zhou F; Chen X; Wu L; Sun L; Han J
    Mol Pharm; 2021 Aug; 18(8):2906-2923. PubMed ID: 34240881
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism.
    Mroz PA; Finan B; Gelfanov V; Yang B; Tschöp MH; DiMarchi RD; Perez-Tilve D
    Mol Metab; 2019 Feb; 20():51-62. PubMed ID: 30578168
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Body weight lowering effect of glucose-dependent insulinotropic polypeptide and glucagon-like peptide receptor agonists is more efficient in RAMP1/3 KO than in WT mice.
    Leuthardt AS; Boyle CN; Raun K; Lutz TA; John LM; Le Foll C
    Eur J Pharmacol; 2023 Sep; 955():175912. PubMed ID: 37454968
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rapid selection of a novel GLP-1/GIP dual receptor agonist with prolonged glycemic control and weight loss in rodent animals.
    Wu Y; Ji T; Lv J; Wang Z
    Life Sci; 2020 Sep; 257():118025. PubMed ID: 32598933
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of biased agonism mediated by dual agonists of the GLP-1 and glucagon receptors.
    Darbalaei S; Yuliantie E; Dai A; Chang R; Zhao P; Yang D; Wang MW; Sexton PM; Wootten D
    Biochem Pharmacol; 2020 Oct; 180():114150. PubMed ID: 32682761
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incretin-Based Multi-Agonist Peptides Are Neuroprotective and Anti-Inflammatory in Cellular Models of Neurodegeneration.
    Kopp KO; Li Y; Glotfelty EJ; Tweedie D; Greig NH
    Biomolecules; 2024 Jul; 14(7):. PubMed ID: 39062586
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice.
    Knerr PJ; Mowery SA; Douros JD; Premdjee B; Hjøllund KR; He Y; Kruse Hansen AM; Olsen AK; Perez-Tilve D; DiMarchi RD; Finan B
    Mol Metab; 2022 Sep; 63():101533. PubMed ID: 35809773
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel glucagon-like peptide-1/glucagon receptor dual agonist exhibits weight-lowering and diabetes-protective effects.
    Zhou J; Cai X; Huang X; Dai Y; Sun L; Zhang B; Yang B; Lin H; Huang W; Qian H
    Eur J Med Chem; 2017 Sep; 138():1158-1169. PubMed ID: 28772236
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of a potent GIPR peptide antagonist that is effective in rodent and human systems.
    Yang B; Gelfanov VM; El K; Chen A; Rohlfs R; DuBois B; Kruse Hansen AM; Perez-Tilve D; Knerr PJ; D'Alessio D; Campbell JE; Douros JD; Finan B
    Mol Metab; 2022 Dec; 66():101638. PubMed ID: 36400403
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diabetes and obesity treatment based on dual incretin receptor activation: 'twincretins'.
    Skow MA; Bergmann NC; Knop FK
    Diabetes Obes Metab; 2016 Sep; 18(9):847-54. PubMed ID: 27160961
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel GIP analogue, ZP4165, enhances glucagon-like peptide-1-induced body weight loss and improves glycaemic control in rodents.
    Nørregaard PK; Deryabina MA; Tofteng Shelton P; Fog JU; Daugaard JR; Eriksson PO; Larsen LF; Jessen L
    Diabetes Obes Metab; 2018 Jan; 20(1):60-68. PubMed ID: 28598027
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of Fc fusion protein glucagon-like peptide-1 and glucagon dual receptor agonist with different receptor selectivity in vivo studies.
    Jiang P; Zeng Y; Yang W; Li L; Zhou L; Xiao L; Li Y; Gu B; Li X; Li J; Li W; Guo L
    Biomed Pharmacother; 2024 May; 174():116485. PubMed ID: 38518602
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structural insights into multiplexed pharmacological actions of tirzepatide and peptide 20 at the GIP, GLP-1 or glucagon receptors.
    Zhao F; Zhou Q; Cong Z; Hang K; Zou X; Zhang C; Chen Y; Dai A; Liang A; Ming Q; Wang M; Chen LN; Xu P; Chang R; Feng W; Xia T; Zhang Y; Wu B; Yang D; Zhao L; Xu HE; Wang MW
    Nat Commun; 2022 Feb; 13(1):1057. PubMed ID: 35217653
    [TBL] [Abstract][Full Text] [Related]  

  • 20. GIP and GLP-2 together improve bone turnover in humans supporting GIPR-GLP-2R co-agonists as future osteoporosis treatment.
    Gabe MBN; Skov-Jeppesen K; Gasbjerg LS; Schiellerup SP; Martinussen C; Gadgaard S; Boer GA; Oeke J; Torz LJ; Veedfald S; Svane MS; Bojsen-Møller KN; Madsbad S; Holst JJ; Hartmann B; Rosenkilde MM
    Pharmacol Res; 2022 Feb; 176():106058. PubMed ID: 34995796
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.